TET2 inhibition in B cells decelerates HCC progression by preventing the generation of IL-10+ B cells, thereby enhancing the antitumor response of CD8+ T cells and facilitating antitumor immunity to improve anti-PD-1 therapy for HCC17. Here, IL10 is linked to hepatocellular carcinoma.